The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre

Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile o...

詳細記述

書誌詳細

主要な著者:	Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2024-12-01
シリーズ:	Current Oncology
主題:	trastuzumab deruxtecan TDXd antibody–drug conjugate breast cancer
オンライン･アクセス:	https://www.mdpi.com/1718-7729/32/1/1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!